MX2016016139A - Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5. - Google Patents

Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5.

Info

Publication number
MX2016016139A
MX2016016139A MX2016016139A MX2016016139A MX2016016139A MX 2016016139 A MX2016016139 A MX 2016016139A MX 2016016139 A MX2016016139 A MX 2016016139A MX 2016016139 A MX2016016139 A MX 2016016139A MX 2016016139 A MX2016016139 A MX 2016016139A
Authority
MX
Mexico
Prior art keywords
complement
complement pathway
polymorphism
patients
treatment
Prior art date
Application number
MX2016016139A
Other languages
English (en)
Spanish (es)
Inventor
H Weston-Davies Wynne
Original Assignee
Volution Immuno Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals Sa filed Critical Volution Immuno Pharmaceuticals Sa
Publication of MX2016016139A publication Critical patent/MX2016016139A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2016016139A 2014-06-06 2015-06-08 Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5. MX2016016139A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1410116.6A GB201410116D0 (en) 2014-06-06 2014-06-06 Method of treatment
PCT/EP2015/062742 WO2015185760A1 (en) 2014-06-06 2015-06-08 Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism

Publications (1)

Publication Number Publication Date
MX2016016139A true MX2016016139A (es) 2017-07-28

Family

ID=51266841

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016139A MX2016016139A (es) 2014-06-06 2015-06-08 Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5.

Country Status (16)

Country Link
US (3) US11052129B2 (ja)
EP (1) EP3151851B1 (ja)
JP (2) JP7045133B2 (ja)
KR (1) KR102439717B1 (ja)
CN (1) CN106659767B (ja)
AU (1) AU2015270396B2 (ja)
BR (1) BR112016028446A2 (ja)
CA (1) CA2951175A1 (ja)
DK (2) DK3151851T3 (ja)
ES (2) ES2906630T3 (ja)
GB (1) GB201410116D0 (ja)
IL (1) IL249237B (ja)
MX (1) MX2016016139A (ja)
PL (2) PL3151851T3 (ja)
RU (1) RU2700932C2 (ja)
WO (1) WO2015185760A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
CA2988313A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201602802D0 (en) * 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
US20190225678A1 (en) * 2016-06-07 2019-07-25 Novartis Ag Anti-c5 antibody for treating patients with complement c5 polymorphism
SE540754C2 (en) * 2016-11-30 2018-10-30 Ikea Supply Ag Molding of fiber blanks into three-dimensional fiber block
PL3612208T3 (pl) * 2017-04-21 2023-07-24 Volution Immuno Pharmaceuticals Sa Coversin do leczenia autoimmunologicznych chorób pęcherzowych
EP3612206A1 (en) * 2017-04-21 2020-02-26 Volution Immuno Pharmaceuticals SA Coversin for the treatment of cicatrising eye inflammatory disorders
WO2019186084A1 (en) * 2018-03-26 2019-10-03 The University Of Liverpool Anti-complement histones
JP2022500389A (ja) * 2018-09-10 2022-01-04 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054033A9 (en) 1995-08-30 2005-03-10 Human Genome Sciences, Inc. Methods and compositions for treating and preventing infection using human interferon regulatory factor 3
GB0312619D0 (en) * 2003-06-02 2003-07-09 Evolutec Ltd Complement inhibitors
AU2004242759B2 (en) 2003-06-02 2009-11-26 Volution Immuno Pharmaceuticals Sa Complement inhibitors from ticks
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
CA2662716C (en) * 2006-09-08 2017-11-21 Varleigh Limited Method of treating respiratory disorders
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
CN102762223B (zh) * 2010-01-08 2014-09-03 沃卢申伊谬诺制药公司 用于治疗呼吸道病毒性感染的ev576
TW201418707A (zh) 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
PL3612208T3 (pl) 2017-04-21 2023-07-24 Volution Immuno Pharmaceuticals Sa Coversin do leczenia autoimmunologicznych chorób pęcherzowych

Also Published As

Publication number Publication date
AU2015270396A1 (en) 2016-12-15
IL249237B (en) 2020-09-30
RU2700932C2 (ru) 2019-09-24
WO2015185760A1 (en) 2015-12-10
EP3151851A1 (en) 2017-04-12
DK3302519T3 (da) 2022-02-28
JP2018516944A (ja) 2018-06-28
CA2951175A1 (en) 2015-12-10
RU2016151179A (ru) 2018-07-16
RU2016151179A3 (ja) 2019-01-22
US20170196936A1 (en) 2017-07-13
JP6767396B2 (ja) 2020-10-14
US11052129B2 (en) 2021-07-06
US20210283221A1 (en) 2021-09-16
CN106659767B (zh) 2022-08-30
IL249237A0 (en) 2017-02-28
JP7045133B2 (ja) 2022-03-31
KR102439717B1 (ko) 2022-09-02
ES2906632T3 (es) 2022-04-19
JP2017518316A (ja) 2017-07-06
EP3151851B1 (en) 2021-12-01
ES2906630T3 (es) 2022-04-19
GB201410116D0 (en) 2014-07-23
US20180193417A1 (en) 2018-07-12
DK3151851T3 (da) 2022-02-28
KR20170016893A (ko) 2017-02-14
AU2015270396B2 (en) 2020-07-16
PL3302519T3 (pl) 2022-04-25
CN106659767A (zh) 2017-05-10
PL3151851T3 (pl) 2022-04-04
NZ727053A (en) 2023-10-27
BR112016028446A2 (pt) 2017-10-24

Similar Documents

Publication Publication Date Title
MX2016016139A (es) Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5.
MA40290A1 (fr) Agents immunorégulateurs
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
BR112015020466A2 (pt) inibidores de cdc7
SG10201811185YA (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MX2015012520A (es) Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion.
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
NZ721500A (en) Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
CL2019000625A1 (es) Combinación de agonistas de fxr.
PH12016502244A1 (en) Hsp70 modulators and methods for making and using the same
PH12015502266A1 (en) Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical